Nadmed

Helsinki, Finland· Est. 2019

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Nadmed is a Helsinki-based diagnostics company that has developed a proprietary, colorimetric method for precisely measuring all four NAD types and glutathione from minimal blood samples. Originating from research at the University of Helsinki, its CE-marked kits and lab services cater to clinical trials, research institutions, and diagnostic labs globally. The company is capitalizing on the growing scientific and commercial interest in NAD as a biomarker for aging, metabolic disorders, and neurodegenerative diseases, partnering with biotechs and CROs to integrate its testing into drug development and personalized health.

Mitochondrial DiseasesNeurodegenerative DisordersMetabolic HealthAging/Longevity

Technology Platform

Proprietary colorimetric assay for individual quantification of all four NAD metabolites (NAD+, NADH, NADP+, NADPH) and two glutathione states from minimal blood, tissue, or cell samples. CE-marked for clinical blood use.

Opportunities

The rapid growth of the longevity and precision health markets creates massive demand for accessible biomarker tests.

Nadmed's first-mover advantage with a CE-marked, easy-to-use NAD test allows it to capture market share in clinical diagnostics, pharmaceutical R&D, and direct-to-consumer testing channels.

Strategic partnerships with larger diagnostic firms or pharma companies could accelerate global adoption.

Risk Factors

Commercial success depends on the broader medical acceptance of NAD as a standard clinical biomarker, which is not yet guaranteed.

The company faces competition from established lab methods (e.g., LC-MS) and potential new entrants.

As a focused, private company, it may have limited resources for large-scale clinical validation and global commercial expansion compared to larger diagnostics corporations.

Competitive Landscape

Nadmed competes with academic and core laboratories that use in-house LC-MS methods for NAD measurement, which can be costly and complex. Other diagnostic companies may offer single-analyte or ratio-based tests. Nadmed's key differentiators are its ability to measure all individual metabolites with a simple, cost-effective, and CE-marked colorimetric kit, positioning it uniquely for clinical lab adoption.